This is a case study on the counter strategy of latecomer
pharmaceutical company against evegreening strategy of multinational leading pharmaceuticals.
H-Pharmaceutical focused on the acquisition of simple production skills for the synthetic raw mater...
This is a case study on the counter strategy of latecomer
pharmaceutical company against evegreening strategy of multinational leading pharmaceuticals.
H-Pharmaceutical focused on the acquisition of simple production skills for the synthetic raw materials at the initial periods and it continued process innovation. After that, it focused on product innovation regarding what is called, first generic, and Incrementally Modified Drugs(IMDs).
A way of learning of technological capability in H-Pharmaceutical evolved from learning by execution (which means learning by trial and error based action) to one by investment(which means learning by investing money for R&D).
And advances in capability accumulation made it possible continuous growth even when market have required IMD-related technological competencies.
In addition, experiencing several patent disputes with multinational leading pharmaceutical companies, H-Pharmaceutical company's patent strategy changed from passive and defensive stance to aggressive and offensive one, and such transition made it possible H's fast catching-up.
Based on these accumulated technological and patent-related capabilities and strategies, H, one of domestic leading pharmaceuticals, could make inroads into U.S market with IMD.
As a result, H invalidated evergreening strategy of multinational pharmaceutical company, which other domestic companies did not overcome. and this could be an important implication to other domestic companies in catching-up position.